Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -360.37%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-231.48%
RETURN ON EQUITY (ROE) AVG 3Y
-82.73%
RETURN ON EQUITY (ROE) AVG 5Y
-63.69%
RETURN ON EQUITY (ROE) AVG 10Y
-54.47%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Celcuity Inc.
Market Cap
$3.55B
Return on Equity (ROE)
N/A
TTM Avg
-231.48%
3Y Avg
-82.73%
5Y Avg
-63.69%
Market Cap
$3.56B
Return on Equity (ROE)
-14.60%
TTM Avg
-18.51%
3Y Avg
-18.00%
5Y Avg
-17.65%
Market Cap
$3.52B
Return on Equity (ROE)
-7.50%
TTM Avg
-76.90%
3Y Avg
-65.24%
5Y Avg
-51.68%
Market Cap
$3.41B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.44B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
Market Cap
$3.40B
Return on Equity (ROE)
-80.46%
TTM Avg
-68.44%
3Y Avg
592.63%
5Y Avg
329.15%
Market Cap
$3.39B
Return on Equity (ROE)
N/A
TTM Avg
336.99%
3Y Avg
336.99%
5Y Avg
336.99%
Market Cap
$3.98B
Return on Equity (ROE)
1.40%
TTM Avg
-2.98%
3Y Avg
-2.73%
5Y Avg
0.21%
Market Cap
$3.12B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.55B | N/A | -231.48% | -82.73% | -63.69% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.56B | -14.60% | -18.51% | -18.00% | -17.65% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -7.50% | -76.90% | -65.24% | -51.68% |
| CareDx, Inc (CDNA)vs › | $3.41B | 26.08% | 3.42% | -20.94% | -16.18% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 29.12% | 31.38% | -1.34% | -13.55% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.40B | -80.46% | -68.44% | 592.63% | 329.15% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.39B | N/A | 336.99% | 336.99% | 336.99% |
| ICU Medical, Inc. (ICUI)vs › | $3.98B | 1.40% | -2.98% | -2.73% | 0.21% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.12B | -61.24% | -42.47% | -32.58% | -25.72% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | -11.83% | -25.64% | -7.84% | -12.83% |
ROE
N/A
ROA
-27.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -360.37% |
| 2025-12-31 | -176.06% |
| 2025-09-30 | -139.12% |
| 2025-06-30 | -335.12% |
| 2025-03-31 | -146.73% |
| 2024-12-31 | -96.68% |
| 2024-09-30 | -62.77% |
| 2024-06-30 | -46.74% |
| 2024-03-31 | -54.92% |
| 2023-12-31 | -45.63% |
| 2023-09-30 | -60.83% |
| 2023-06-30 | -44.49% |
| 2023-03-31 | -36.01% |
| 2022-12-31 | -30.18% |
| 2022-09-30 | -81.66% |
| 2022-06-30 | -57.67% |
| 2022-03-31 | -56.46% |
| 2021-12-31 | -43.09% |
| 2021-09-30 | -34.11% |
| 2021-06-30 | -80.82% |
| 2021-03-31 | -28.48% |
| 2020-12-31 | -80.96% |
| 2020-09-30 | -63.45% |
| 2020-06-30 | -51.96% |
| 2020-03-31 | -44.31% |
| 2019-12-31 | -38.14% |
| 2019-09-30 | -35.61% |
| 2019-06-30 | -32.43% |
| 2019-03-31 | -30.84% |
| 2018-12-31 | -29.51% |
| 2018-09-30 | -27.42% |
| 2018-06-30 | -25.53% |
| 2018-03-31 | -24.15% |
| 2017-12-31 | -19.92% |
| 2017-09-30 | -16.55% |
| 2017-06-30 | -104.61% |
| 2017-03-31 | -75.80% |
| 2016-12-31 | -58.99% |
